Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $2.9 million.

  • Caribou Biosciences' Share-based Compensation fell 27.97% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 15.28%. This contributed to the annual value of $16.7 million for FY2024, which is 21.50% up from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Share-based Compensation is $2.9 million, which was down 6.33% from $3.1 million recorded in Q2 2025.
  • Caribou Biosciences' Share-based Compensation's 5-year high stood at $4.7 million during Q2 2024, with a 5-year trough of $343,000 in Q1 2021.
  • Its 3-year average for Share-based Compensation is $3.7 million, with a median of $3.6 million in 2023.
  • In the last 5 years, Caribou Biosciences' Share-based Compensation skyrocketed by 781.63% in 2022 and then slumped by 33.96% in 2025.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Share-based Compensation stood at $1.6 million in 2021, then spiked by 96.51% to $3.1 million in 2022, then climbed by 14.67% to $3.6 million in 2023, then increased by 9.98% to $3.9 million in 2024, then declined by 27.97% to $2.9 million in 2025.
  • Its Share-based Compensation was $2.9 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.9 million in Q1 2025.